Publications

There are published preclinical studies by both independent researchers as well as by Metro International Biotech founders and advisors in leading scientific and medical journals, establishing the potential of enhanced NAD+ levels for rare mitochondrial, aging-related and more mainstream diseases.

Clinical and preclinical evidence that disease and age-related functional decline can be mitigated by boosting NAD+

Oral MIB- 626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levelsin Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial. June 18, 2025

Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID-19. December 23, 2024

NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich’s Ataxia. August 22, 2024

Fertility protection during chemotherapy treatment by boosting the NAD(P)+ metabolome. August 21, 2024

Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. February 6, 2023

MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. March 1, 2022

Supplementation with an NAD precursor delayed motor neuron degeneration, decreased markers of neuroinflammation in the spinal cord increased survival in a mouse model of ALS. May 1, 2020

Nicotinamide mononucleotide preserves mitochondrial function and increases survival in hemorrhagic shock. September 6, 2018

NAD precursor improves blood flow and musculoskeletal endurance in elderly mice. March 22, 2018

An NAD precursor reduced Aβ deposits in worms and in the cortex tissues of mice with Alzheimer’s Disease. December 14, 2017